A phase II trial of uracil ointment for the prevention of capecitabine induced hand-foot syndrome (HFS): .

A phase II trial of uracil ointment for the prevention of capecitabine induced hand-foot syndrome (HFS): . - P2 trial of uracil ointment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013098

Enrollment

Registered

2014-02-14

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or recurrent breast cancer

Interventions

Uracil ointment application to the palmar and plantar skin.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Histologically confirmed advanced or recurrent breast cancer.

Exclusion criteria

Exclusion criteria: Had previous treatment with capecitabine.

Design outcomes

Primary

Measure	Time frame
Incidence and appearance time of Grade 2 HFS.	—

Countries

Japan

Contacts

Public ContactTetsuya Taguchi

Kyoto Prefectural University of medicine Department of Endocrine & Breast Surgery

breast@koto.kpu-m.ac.jp075-251-5534

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026